Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies

Joshua D. Brown * and Val R. Adams

Institute for Pharmaceutical Outcomes and Policy, Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA; val.adams@uky.edu
* Correspondence: josh.brown@uky.edu; Tel.: +1-859-218-0229

Academic Editor: Sampath Parthasarathy
Received: 29 December 2015; Accepted: 23 February 2016; Published: 26 February 2016

Abstract: Multiple myeloma (MM) has an inherent high risk of thromboembolic events associated with patient as well as disease- and treatment-related factors. Previous studies have assessed the association of MM-related thromboembolism using “traditional” Kaplan–Meier (KM) and/or Cox proportional hazard (PH) regression. In the presence of high incidence of death, as would be the case in cancer patients with advanced age, these statistical models will produce bias estimates. Instead, a competing risk framework should be used. This study assessed the baseline patient demographic and clinical characteristics associated with MM-related thromboembolism and compared the cumulative incidence and the measures of association obtained using each statistical approach. The cumulative incidence of thromboembolism was 9.2% using the competing risk framework and nearly 12% using the KM approach. Bias in the measures of covariate risk associations was highest for factors related to risk of death such as increased age (75% bias) and severe liver disease (50%) for the Cox PH model compared to the competing risk model. These results show that correct specification of statistical techniques can have a large impact on the results obtained.

Keywords: venous thromboembolism; multiple myeloma; competing risks

1. Introduction

Compared to the general population, individuals with cancer are at 4 to 7 times higher risk of developing a venous thromboembolism (VTE) [1–4]. Malignancy induces a prothrombotic state which includes activation of the coagulation cascade, increase in pro-inflammatory cytokines, as well as inhibition of natural anticoagulants and is further exacerbated by cancer treatment and surgery [5–7]. Other risk factors for VTE in cancer include the site and stage of the tumor, older age, prior history of clots, and comorbidities [6,8–10]. Although at an already increased risk of death from cancer, VTE carries a substantial risk of mortality with clotting events accounting for up to 10% of all deaths in patients with cancer [11–13].

Multiple myeloma (MM) has one of the highest risks of thrombosis among all cancers due to disease-related pathological changes and treatment [7,14]. Thalidomide and lenalidomide (IMIDs) are well known to be associated with increased risk of thrombosis [15], especially when combined with high-dose steroids and other chemotherapy, with incidence approaching 25% in some studies [16–19]. Other common MM treatments include proteasome inhibitors (PIs; bortezomib, carfilzomib) and cytotoxic therapies (cyclophosphamide, melphalan, others), which have been shown to have a lower,
though still increased, risk of VTE compared to IMIDs [20]. Other disease-related factors with potential to increase thrombotic risk include use of central venous catheters (CVC), erythropoietin agents, hospitalization, and infection [6,10,21–26]. Due to this inherent increased risk of thrombosis with MM, guidelines U.S. guidelines recommend routine thromboprophylaxis with low-molecular weight heparins (LMWH) or aspirin [27,28].

These previous studies have assessed VTE risk in MM during randomized-controlled trials (RCTs) comparing alternative treatment strategies or in small observational utilizing “traditional” Kaplan–Meier and/or Cox proportional hazard models. In these statistical frameworks, death is considered a censoring event. This violates a basic assumption that censoring events and the outcome of interest must be independent of each other, meaning that censoring is uninformative. However, given that the occurrence of death prevents the outcome from ever occurring, death competes with the outcome and should not be considered a censoring event [29]. Instead, a competing risks framework should be used which treats death as a separate outcome. A study by Ay et al. [29] compared traditional methods to competing risk methods and found significant bias when ignoring death as a competing risk with VTE incidence during cancer. They observed that the bias in the cumulative incidence of thromboembolism is a function of the incidence of the competing risk. This study did not look at individual factors that may be associated with thromboembolism and how estimates of relative association may be impacted by these methods.

The objective of this study was to determine the one-year incidence of thrombotic events in MM and to assess the association of baseline characteristics and thrombosis in these patients while comparing traditional time-to-event methods with competing risk methods. This study compared risk associations between the two statistical frameworks as applied to this specific cancer type and calculated the bias that would be observed with “traditional” methods.

2. Materials and Methods

2.1. Data Source

This was a retrospective cohort study utilizing Truven Health Analytics MarketScan Commercial Claims and Encounters and Medicare Supplemental databases during the years 2008–2013. The MarketScan data are administrative claims data including medical diagnostic and procedural billing information and pharmacy fill records for those with commercial insurance linked to demographic and insurance enrollment information for each individual. The data include information regarding medical encounters for nearly 40 million persons each year and are representative of the commercially insured population in the U.S.

2.2. Patient Inclusion

We included patients with at least two separate claims with a diagnosis of MM (ICD-9: 203.0x) at least 14 days apart. For further inclusion, subjects were required to have a minimum of 6 months of continuous medical and pharmacy insurance coverage prior to the first MM diagnosis and be at least 18 years or older at diagnosis. Subjects also could not have a previous diagnosis of another cancer or a thrombotic outcome event during the 6-month, pre-index period.

2.3. Subject Characteristics

Age was assessed on the MM index date and gender was linked from the enrollment file. The Charlson Comorbidity Index was used to assess comorbidity burden based on the ICD-9-CM coding algorithm [30] and the total score was further categorized by 0, 1–2, 3–4, and 5+ groups with individual comorbidities also reported. Additional comorbidities of interest were also assessed during the 6 month pre-index period, including thrombocytosis (ICD-9: 238.71, 289.9), leukocytosis (ICD-9: 288.5), anemia (ICD-9: 280.x–285.x), obesity (ICD-9: 278.01–278.03, V85.3, V85.4), hypocoagulopathies (ICD-9: 286.x)
2.4. Outcome Events

DVT and PE events were assessed based on previously published ICD-9-CM algorithms [31–33]. PVT was identified by ICD-9-CM code 452.x and AT identified by ICD-9-CM code 444.x. Date of death was based on discharge status codes on hospital or hospice records and loss to follow-up occurred when continuous insurance coverage ended during the follow-up period or follow-up terminated at the end of the data (December 2013). All other individuals were censored after one year of follow-up. If a thrombosis occurred on the same day as death, the event was recorded as the thrombosis as it was the main outcome of interest in this study. Subjects were followed until one of the following occurred: (1) a thrombosis event; (2) death; (3) loss to follow-up; or (4) end of the 1 year study period.

2.5. Survival Analysis

Person time was calculated correcting for the differential follow-up of each subject. The incidence rate of thrombosis was reported as the rate per 1000 person-years. The association of thrombosis with baseline demographic and clinical characteristics at diagnosis was assessed using a competing risks regression model. In this model the dependent outcome has three levels, \(0 = \text{censored}, 1 = \text{thrombosis},\) and \(2 = \text{death}\). Subdistribution hazard ratios (HR) and their 95% confidence intervals (CI) for the association between each baseline covariate and thrombotic events were estimated for each baseline covariate included in the model. For demonstration of the selection of statistical methods, a Cox proportional hazard (PH) model was also constructed wherein death was considered a censoring event and not a competing risk and included the same specification as the competing risks model. Bias of the Cox PH model HRs was calculated as the relative difference between the Cox HR and the competing risk HR and is reported as the percent bias. The one-year cumulative incidence of thrombotic events was reported for the total cohort by the Fine and Gray method for competing risks. One minus the Kaplan–Meier estimate was used to plot the cumulative probability of thromboembolism, ignoring the competing risk of death. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). The University of Kentucky Institutional Review Board approved the use of the data for this study.

3. Results

3.1. Incidence of Thrombosis

There were 1050 thrombosis events observed in 13,700 individuals during the one-year follow-up. This included 756 DVTs (72% of events), 238 PEs (22.7%), 51 ATs (4.9%), and 5 PVTs (0.5%). Nearly one-half (\(N = 520, 49.5\%\) of events) occurred within the first 90 days after MM diagnosis. Table 1 includes the demographics and clinical characteristics of the cohort.

| Table 1. Baseline characteristics of the cohort at diagnosis of multiple myeloma. |
|---------------------------------------------------------------|
| **Age** | \(N = 13,700\) | **Mean 63.9** | **SD 13.7** |
| 18–34 | 283 | 2.1 |
| 35–64 | 7389 | 53.9 |
| 65–74 | 2648 | 19.3 |
| 75+ | 3380 | 24.7 |
Table 1. Cont.

| Overall Cohort | \(N = 13,700\) |
|----------------|-----------------|
| Gender         |                 |
| Male           | 6625            | 48.4 |
| Female         | 7075            | 51.6 |
| Charlson Comorbidity Index | Mean 1.1 | SD 1.5 |
| 0              | 6892            | 50.3 |
| 1–2            | 4758            | 34.7 |
| 3–4            | 1476            | 10.8 |
| 5+             | 574             | 4.2  |
| Comorbidity    |                 |
| MI             | 251             | 1.8  |
| CHF            | 933             | 6.8  |
| PVD            | 841             | 6.1  |
| Dementia       | 123             | 0.9  |
| COPD           | 1817            | 13.3 |
| Rheumatism     | 734             | 5.4  |
| PUD            | 134             | 1.0  |
| Mild liver disease | 551        | 4.0  |
| Diabetes       | 2814            | 20.5 |
| Diabetes with complications | 755        | 5.5  |
| Paralysis      | 68              | 0.5  |
| Renal disease  | 1826            | 13.3 |
| Severe liver disease | 45         | 0.3  |
| CVD            | 910             | 6.6  |
| HIV/AIDS       | 30              | 0.2  |
| Hypertension   | 6466            | 47.2 |
| CHD            | 1725            | 12.6 |
| Lipids         | 4260            | 31.1 |
| High platelets | 70              | 0.5  |
| High white cell| 270             | 2.0  |
| Anemia         | 3727            | 27.2 |
| Obesity        | 491             | 3.6  |
| Hypocoagulopathies | 544       | 4.0  |
| Thrombocytopenia| 363             | 2.7  |
| Low white cell | 237             | 1.7  |
| Year of Diagnosis |        |     |
| 2009           | 2469            | 18.0 |
| 2010           | 2476            | 18.1 |
| 2011           | 3153            | 23.0 |
| 2012           | 3053            | 22.3 |
| 2013           | 2549            | 18.6 |

CHF = congestive heart failure; PVD = peripheral vascular diseases; COPD = chronic obstructive pulmonary disease; PUD = peptic ulcer disease; CVD = cerebrovascular disease; CHD = coronary heart disease; SD = standard deviation.

The cohort contributed 9791.4 person-years of follow-up time for a one-year incidence rate of thrombosis of 107.2 (95% CI, 100.0–113.9) events per 1000 person-years. The highest incidence of thrombosis was in the first 30 days, with 251 events and an incidence rate of 234.2 (95% CI, 206.5–264.5) per 1000 person-years. The rate of thrombotic events decreased over the 60, 90, and 180 day intervals: 196.6 (95% CI, 178.3–216.4), 171.7 (95% CI, 157.4–187.0), 140.1 (95% CI, 130.5–150.1), per 1000 person-years, respectively. There were 384 deaths experienced as a competing risk and a total of 479 deaths during the study period with an incidence rate of 48.9 (95% CI, 44.7–53.5) deaths per
1000 person-years. The one-year cumulative incidence of thrombosis was 9.2% (95% CI, 8.7%–9.7%) for the total cohort (Figure 1) in the competing risk framework. Additionally, Figure 1 shows that the Kaplan–Meier method overestimates the cumulative incidence, which underlies the statistical models.

### 3.2. Survival Model Results

Table 2 demonstrates the bias introduced by using Cox PH models in the presence of competing risks. The highest bias can be observed in factors that would hypothetically be more associated with the omitted competing risk such as severe comorbidities and increasing age. For example, if competing risks are omitted, a much stronger association is observed between the 75+ age group and VTE, which represents a 75% bias over the competing risks estimate. Older age was associated with an increase in the hazard of thrombosis for the 35–64 and 65–74 age groups compared to the 18–34 reference group (Table 2). Female gender showed a protective effect with HR = 0.7 (95% CI, 0.7–0.8) compared to males. Increasing comorbidity burden had no impact on the hazard of thrombosis at baseline; however, some individual comorbidities at baseline did increase the risk. Those with CHF had 70% higher hazard (HR = 1.7 (95% CI, 1.4–2.1)) and those with hypertension had 20% higher hazard (HR = 1.2 (95% CI, 1.0–1.3)). Diagnosis with both leukocytosis (HR = 1.3 (95% CI, 1.0–1.9)) and leukopenia (HR = 0.9 (95% CI, 1.1–2.2)) had increased hazard of thrombosis in this population. There were no other significant associations observed for the other included covariates.

| Covariate | sHR | 95% CI | HR | 95% CI | % Bias |
|-----------|-----|--------|----|--------|--------|
| **Age**   |     |        |    |        |        |
| 18–34     | Ref. | Ref.   | Ref. | Ref.   | Ref.   |
| * 35–64   | 1.7 | 1.0    | 3.0 | 2.2    | 1.3    | 3.7    | 29.4%  |
| * 65–74   | 1.9 | 1.1    | 3.2 | 2.4    | 1.4    | 4.1    | 26.3%  |
| 75+       | 1.6 | 0.9    | 2.7 | 2.8    | 1.6    | 4.8    | 75.0%  |
| **Gender**|     |        |    |        |        |
| Male      | Ref. | Ref.   | Ref. | Ref.   | Ref.   |
| * Female  | 0.7 | 0.7    | 0.8 | 0.7    | 0.7    | 0.8    | 0.0%   |

Figure 1. Comparison of Kaplan–Meier (black) and competing risk (gray) cumulative incidence functions of thromboembolic events.
Table 2. Cont.

| Covariate                     | Competing Risks | Cox PH |
|-------------------------------|-----------------|--------|
|                               | sHR  | 95% CI | HR   | 95% CI | % Bias |
| Charlson Comorbidity Index    |      |        |      |        |        |
| 0 Ref. Ref. Ref. Ref. Ref.    |      |        |      |        |        |
| 1–2 1.0 0.5 2.1 1.0 0.8 1.2 0.0% |      |        |      |        |        |
| 3–4 0.8 0.5 1.3 0.8 0.6 1.2 0.0% |      |        |      |        |        |
| 5+ 1.0 0.8 1.2 0.9 0.5 1.7 10.0% |      |        |      |        |        |
| Comorbidities |      |        |      |        |        |
| MI 0.9 0.6 1.4 1.1 0.8 1.5 22.2% |      |        |      |        |        |
| *CHF 1.7 1.4 2.1 1.9 1.6 2.3 11.8% |      |        |      |        |        |
| PVD 1.2 0.9 1.5 1.2 1.0 1.4 0.0% |      |        |      |        |        |
| Dementia 1.2 0.7 2.1 1.5 0.9 2.3 25.0% |      |        |      |        |        |
| COPD 0.9 0.8 1.1 1.1 0.9 1.3 22.2% |      |        |      |        |        |
| Rheumatism 0.9 0.6 1.2 0.7 0.5 1.0 22.2% |      |        |      |        |        |
| PUD 0.8 0.5 1.5 1.0 0.7 1.6 25.0% |      |        |      |        |        |
| Mild liver disease 0.8 0.5 1.1 0.9 0.7 1.2 12.5% |      |        |      |        |        |
| Diabetes 1.0 0.8 1.2 1.1 0.9 1.2 10.0% |      |        |      |        |        |
| Diabetes with complications 1.1 0.8 1.5 1.0 0.7 1.3 39.1% |      |        |      |        |        |
| Paralysis 1.4 0.8 2.5 1.2 0.7 2.0 14.3% |      |        |      |        |        |
| Renal disease 1.0 0.8 1.3 1.0 0.8 1.3 0.0% |      |        |      |        |        |
| Severe liver disease 1.1 0.4 3.0 1.7 0.9 3.4 54.5% |      |        |      |        |        |
| CVD 1.0 0.8 1.3 1.1 0.9 1.4 10.0% |      |        |      |        |        |
| *Hypertension 1.2 1.0 1.3 1.1 1.0 1.3 39.3% |      |        |      |        |        |
| CHD 1.0 0.8 1.1 1.0 0.9 1.1 0.0% |      |        |      |        |        |
| Lipids 1.0 0.9 1.1 1.0 0.9 1.1 0.0% |      |        |      |        |        |
| High platelets 1.0 0.5 2.1 1.0 0.5 1.8 0.0% |      |        |      |        |        |
| *High white cell 1.3 1.0 1.9 1.2 0.9 1.6 7.7% |      |        |      |        |        |
| Anemia 0.9 0.8 1.1 1.0 0.9 1.6 11.1% |      |        |      |        |        |
| Obesity 1.2 0.9 1.6 1.1 0.9 1.4 8.3% |      |        |      |        |        |
| Hypocoagulopathies 0.9 0.6 1.4 0.8 0.6 1.3 11.1% |      |        |      |        |        |
| Thrombocytopenia 1.0 0.6 1.8 1.2 0.8 2.0 20.0% |      |        |      |        |        |
| *Low white cell 1.6 1.1 2.2 1.4 1.0 1.9 12.5% |      |        |      |        |        |

sHR = subdistribution hazard ratio; CI = confidence interval; MI = myocardial infarction; CHF = congestive heart failure; PUD = peptic ulcer disease; CVD = cerebrovascular disease; CHD = coronary heart disease; Ref. = Reference category; * p < 0.05.

4. Discussion

Treatment advances over the last decade for MM have led to an increase in median survival greater than 5 years [34,35]. However, thrombotic complications have emerged as serious adverse effects of treatment driving the consideration of thromboprophylaxis in guidelines and RCTs in this patient population [36,37]. Despite the known risk, the pathogenesis of thrombosis in MM is poorly understood due to the various factors that can impart risk including patient characteristics, disease-related factors, as well as treatment-related risks [7]. Although thrombotic events have not been shown to have a large impact on overall survival specifically in MM [36], thrombosis events can cause interruption in therapy as well as tremendous economic and humanistic burdens in the MM population [38,39]. Recent American Society of Clinical Oncology guidelines have called for better evidence regarding the increased risk of thrombosis and MM so that prevention efforts can be focused towards periods of highest risk [40].

This study investigated two statistical approaches to assess the baseline factors related to thrombosis risk in newly diagnosed MM. For this population the competing risk of death is a contribution by many factors, including the advanced age of the cohort, having cancer, as well as the risk of death from the other outcome events [30]. The primary model used a competing risks framework, given that the outcome events cannot be considered independent of each other, i.e.
experiencing one may preclude experiencing another or one event may cause another. Failure to do so can overestimate survival for traditional Kaplan–Meier or proportional hazard based analyses and lead to inflated cumulative incidence functions and biased associations [30]. In this study, this would have overestimated the cumulative incidence to be nearly 12% over the one-year study period. For measures of association in the regression models, the largest bias was observed for those factors that would be more highly associated with the competing risk. For example, age 75 and older had a HR of 2.8 (95% CI 1.6–4.8) in the Cox PH model. This is compared to the “true” value from the competing risk model of 1.6 (0.9–2.7)—a relative bias of 75%. Likewise, there was significant bias associated with liver disease (54.5%), dementia (25.0%), peptic ulcer disease (25.0%), and chronic pulmonary disease (25.0%). More importantly, as in the case of increasing age and peripheral vascular disease, the bias alters the bounds of the confidence interval to include the null making the interpretation of the findings more tedious.

In the primary analysis, there were few baseline factors found to be associated with risk in this study suggesting that risk may be associated with factors related to treatment of MM instead of pre-existing, patient-related factors. We observed that nearly one-half of all thrombotic events occurred within the first 90 days after MM diagnosis. A similar finding has been found by other studies, suggesting that the risk in the initial stage of diagnosis and treatment may be related to high tumor burden and release of thrombogenic factors with initiation of treatment [16,41,42]. This underscores the need to identify early risk factors at diagnosis to guide the utilization of thromboprophylaxis—especially in the first 90 days of treatment. In a post-hoc analysis restricting events to the first 90 days and in the full model analysis presented here, however, we found few demographic or clinical characteristics that were predictive of outcome events. This suggests that thrombosis risk in this population may be primarily driven by treatment and not necessarily any underlying risk.

Due to the methodological focus and goals of this study, we ignored other factors related to VTE risk in multiple myeloma—mainly chemotherapeutic agents used and utilization of anticoagulant/antiplatelet therapy. It is well known that IMID therapy is associated with a large increase in risk and has led to thromboprophylaxis being commonplace for these patients. Treatment is, by nature, highly time-variant, given ever-changing treatment regimens as well as periods of treatment interspersed with periods of no treatment. This implies the usefulness of time-varying statistical frameworks and represents one of the primary limitations of competing risks analyses, given that competing risks methods are not compatible with time-varying covariates. While it is beyond the scope of this study to address time-varying exposures, we have shown the bias introduced when ignoring competing risks. Thus, there is a tenuous balance between including biased estimates of the survival functions or excluding time-varying covariates. Other methodologies can be utilized as well, such as the case-crossover or case-time-control study designs which avoid these setbacks. This study is subject to several limitations inherent to claims-based studies [43,44]. This study relied on ICD-9 coding available in the claims to diagnose study subjects with outcome events and comorbidities. It is impossible to confirm a positive diagnosis using these data; however, claims-based coding algorithms for VTE have been shown to perform strongly especially when there is a high risk of VTE in the population [32,45]. Further, information regarding MM severity and staging is not available in claims data and, thus, could not be included here. Likewise, medications not obtained using insurance, such as over-the-counter aspirin for thromboprophylaxis, cannot be observed in claims data and was unobserved in this study [46].

5. Conclusions

This study used a competing risks framework given that the outcome events cannot be considered independent of each other, i.e., experiencing one may preclude experiencing another or one event may cause another. Failure to do so can overestimate survival for traditional Kaplan–Meier or proportional hazard based analyses and lead to inflated cumulative incidence functions and biased associations.
In this study, this would have overestimated the cumulative incidence to be nearly 12% over the one-year study period. For this population the competing risk of death is a contribution by many factors including the advanced age of the cohort, having cancer, as well as the risk of death from the other outcome events. Death must be accounted for in older populations as well as in high mortality disease states when the incidence of death is high to avoid potential statistical pitfalls of traditional Kaplan–Meier and Cox PH methods.

**Acknowledgments:** The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Author Contributions:** Joshua D. Brown contributed to the study design, data analysis, interpretation of the results, and the drafting and revision of the manuscript. Val R. Adams contributed to the study design, interpretation of the results, and the editing and revision of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

The following abbreviations are used in this manuscript:

- VTE: venous thromboembolism
- MM: multiple myeloma
- IMID: immunomodulating drugs
- PI: proteasome inhibitors
- CVC: central venous catheters
- LMWH: low-molecular weight heparin
- RCT: randomized controlled trial
- ICD-9-CM: International classification of diseases, 9th revision, clinical modification
- DVT: deep vein thrombosis
- PE: pulmonary embolism
- HR: hazard ratio
- PH: proportional hazard
- CI: confidence interval
- PVT: portal vein thrombosis
- AT: arterial thrombosis
- SD: standard deviation

**References**

1. Timp, J.F.; Braekkan, S.K.; Versteeg, H.H.; Cannegieter, S.C. Epidemiology of cancer-associated venous thrombosis. *Blood* 2013, 122, 1712–1723. [CrossRef] [PubMed]
2. Blom, J.W.; Doggen, C.J.; Osanto, S.; Rosendaal, F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA* 2005, 293, 715–722. [CrossRef] [PubMed]
3. Cronin-Fenton, D.P.; Sondergaard, F.; Pedersen, L.A.; Fryzek, J.P.; Cetin, K.; Acquavella, J.; Baron, J.A.; Sørensen, H.T. Hospitalisation for venous thromboembolism in cancer patients and the general population: A population-based cohort study in Denmark, 1997–2006. *Br. J. Cancer* 2010, 103, 947–953. [CrossRef] [PubMed]
4. Heit, J.A.; Silverstein, M.D.; Mohr, D.N.; Petterson, T.M.; O’Fallon, W.M.; Melton, L.J. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. *Arch. Intern. Med.* 2000, 160, 809–815. [CrossRef] [PubMed]
5. Lip, G.Y.; Chin, B.S.; Blann, A.D. Cancer and the prothrombotic state. *Lancet Oncol.* 2002, 3, 27–34. [CrossRef]
6. Khorana, A.A.; Dalal, M.; Lin, J.; Connolly, G.C. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. *Cancer* 2013, 119, 648–655. [CrossRef] [PubMed]
7. Zamagni, E.; Brioli, A.; Tacchetti, P.; Zannetti, B.; Pantani, L.; Cavo, M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. *Semin. Thromb. Hemost.* **2011**, *37*, 209–219. [CrossRef] [PubMed]

8. Horsted, F.; West, J.; Grainge, M.J. Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. *PloS Med.* **2012**, *9*, e1001275. [CrossRef] [PubMed]

9. Khorana, A.A.; Kuderer, N.M.; Culakova, E.; Lyman, G.H.; Francis, C.W. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood* **2008**, *111*, 4902–4907. [CrossRef] [PubMed]

10. Wun, T.; White, R.H. Venous thromboembolism (VTE) in patients with cancer: Epidemiology and risk factors. *Cancer Investig.* **2009**, *27*, 63–74. [CrossRef] [PubMed]

11. Frere, C.; Debourdeau, P.; Hij, A.; Cajfinger, F.; Onan, M.N.; Panicot-Dubois, L.; Dubois, C.; Farge, D. Therapy for cancer-related thromboembolism. *Semin. Oncol.* **2014**, *41*, 319–338. [CrossRef] [PubMed]

12. Khorana, A.A.; Francis, C.W.; Culakova, E.; Kuderer, N.M.; Lyman, G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. *J. Thromb. Haemost.* **2007**, *5*, 632–634. [CrossRef] [PubMed]

13. Khorana, A.A. Venous thromboembolism and prognosis in cancer. *Thromb. Res.* **2010**, *125*, 490–493. [CrossRef] [PubMed]

14. Srkalovic, G.; Cameron, M.G.; Rybicki, L.; Deitcher, S.R.; Kattke-Marchant, K.; Hussein, M.A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of veno-occlusive disease. *Cancer* **2004**, *101*, 558–566. [CrossRef] [PubMed]

15. Zangari, M.; Anaissie, E.; Barlogie, B.; Badros, A.; Desikan, R.; Gopal, A.V.; Morris, C.; Toor, A.; Siegel, E.; Fink, L.; et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. *Blood* **2001**, *98*, 1614–1615. [CrossRef] [PubMed]

16. Zangari, M.; Siegel, E.; Barlogie, B.; Anaissie, E.; Saghaifar, F.; Fassas, A.; Morris, C.; Fink, L.; Tricot, G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. *Blood* **2002**, *100*, 1168–1171. [CrossRef] [PubMed]

17. Bennett, C.L.; Angelotta, C.; Yarnold, P.R.; Evens, A.M.; Zonder, J.A.; Raisch, D.W.; Richardson, P. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. *JAMA* **2006**, *296*, 2558–2560. [CrossRef] [PubMed]

18. Leleu, X.; Rodon, P.; Hulin, C.; Daley, L.; Dauriac, C.; Hacini, M.; Decaux, O.; Eisemann, J.C.; Fitoussi, O.; Lioure, B.; et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. *Thromb. Haemost.* **2013**, *110*, 844–851. [CrossRef] [PubMed]

19. Carrier, M.; Le Gal, G.; Tay, J.; Wu, C.; Lee, A.Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: A systematic review and meta-analysis. *J. Thromb. Haemost.* **2011**, *9*, 653–663. [CrossRef] [PubMed]

20. Zangari, M.; Fink, L.; Zhan, F.; Tricot, G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: Review of data from phase 3 trials and studies of novel combination regimens. *Clin. Lymphoma Myeloma Leuk.* **2011**, *11*, 228–236. [CrossRef] [PubMed]

21. Bennett, C.L.; Silver, S.M.; Djulbegovic, B.; Samaras, A.T.; Blau, C.A.; Gleason, K.J.; Barnato, S.E.; Elverman, K.M.; Courtney, D.M.; McKoy, J.M.; et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *JAMA* **2008**, *299*, 914–924. [CrossRef] [PubMed]

22. Khorana, A.A.; Francis, C.W.; Culakova, E.; Lyman, G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. *Cancer* **2005**, *104*, 2822–2829. [CrossRef] [PubMed]

23. Lippi, G.; Franchini, M.; Favaloro, E.J. Thrombotic complications of erythropoiesis-stimulating agents. *Semin. Thromb. Hemost.* **2010**, *36*, 537–549. [CrossRef] [PubMed]

24. Beckers, M.M.; Ruven, H.J.; Seldenrijk, C.A.; Prins, M.H.; Biesma, D.H. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. *Thromb. Res.* **2010**, *125*, 318–321. [CrossRef] [PubMed]

25. Shivakumar, S.P.; Anderson, D.R.; Couban, S. Catheter-associated thrombosis in patients with malignancy. *J. Clin. Oncol.* **2009**, *27*, 4858–4864. [CrossRef] [PubMed]
26. Esmon, C.T. Does inflammation contribute to thrombotic events? *Haemostasis* 2000, 30, 34–40. [CrossRef] [PubMed]
27. Lyman, G.H.; Khorana, A.A.; Kuderer, N.M.; Lee, A.Y.; Arcelus, J.I.; Balaban, E.P.; Clarke, J.M.; Flowers, C.R.; Francis, C.W.; Gates, L.E.; et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J. Clin. Oncol.* 2013, 31, 2189–2204. [CrossRef] [PubMed]
28. Anderson, K.C.; Alsina, M.; Atanackovic, D.; Biermann, J.S.; Chandler, J.C.; Costello, C.; Djulbegovic, B.; Fung, H.C.; Gasparetto, C.; Godby, K.; et al. Multiple Myeloma, Version 2.2016. *J. Natl. Compr. Cancer Netw.* 2015, 13, 1398–1435.
29. Ay, C.; Posch, F.; Kaider, A.; Zielinski, C.; Pabinger, I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. *J. Thromb. Haemost.* 2015, 13, 390–397. [CrossRef] [PubMed]
30. Quan, H.; Sundararajan, V.; Halfon, P.; Fong, A.; Burnand, B.; Luthi, J.C.; Saunders, L.D.; Beck, C.A.; Feasby, T.E.; Ghali, W.A. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med. Care* 2005, 43, 1130–1139. [CrossRef] [PubMed]
31. Sanfilippo, K.M.; Wang, T.; Gage, B.F.; Liu, W.; Carson, K.R. Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. *Thromb. Res.* 2015, 135, 616–620. [CrossRef] [PubMed]
32. White, R.H.; Garcia, M.; Sadeghi, B.; Tancredi, D.J.; Zrelak, P.; Cony, J.; Sama, P.; Gammon, H.; Schmalzt, S.; Romano, P.S. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. *Thromb. Res.* 2010, 126, 61–67. [CrossRef] [PubMed]
33. Zhan, C.; Battles, J.; Chiang, Y.P.; Hunt, D. The validity of ICD-9-CM codes in identifying postoperative deep vein thrombosis and pulmonary embolism. *Jt. Comm. J. Qual. Patient Saf.* 2007, 33, 326–331. [PubMed]
34. Mahindra, A.; Laubach, J.; Raje, N.; Munshi, N.; Richardson, P.G.; Anderson, K. Latest advances and current challenges in the treatment of multiple myeloma. *Nat. Rev. Clin. Oncol.* 2012, 9, 135–143. [CrossRef] [PubMed]
35. Kumar, S.K.; Rajkumar, S.V.; Dispensieri, A.; Lacy, M.Q.; Hayman, S.R.; Buadi, F.K.; Zeldenrust, S.R.; Dingli, D.; Russell, S.J.; Lust, J.A.; et al. Improved survival in multiple myeloma and the impact of novel therapies. *Blood* 2008, 111, 2516–2520. [CrossRef] [PubMed]
36. Palumbo, A.; Cavo, M.; Bringhen, S.; Zamagni, E.; Romano, A.; Patriarca, F.; Rossi, D.; Gentilini, F.; Crippa, C.; Galli, M.; et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. *J. Clin. Oncol.* 2011, 29, 986–993. [CrossRef] [PubMed]
37. Larocca, A.; Cavallo, F.; Bringhen, S.; Di Raimondo, F.; Falanga, A.; Evangelista, A.; Cavalli, M.; Stanovsky, A.; Corradini, P.; Pezzatti, S.; et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood* 2012, 119, 933–939. [CrossRef] [PubMed]
38. Khorana, A.A.; Dalal, M.R.; Lin, J.; Connolly, G.C. Health care costs associated with venous thromboembolism and pulmonary embolism. *J. Clin. Oncol.* 2013, 5, 101–108. [CrossRef] [PubMed]
39. Lee, A.Y. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. *J. Clin. Oncol.* 2009, 27, 4895–4901. [CrossRef] [PubMed]
40. Lyman, G.H.; Bohlke, K.; Khorana, A.A.; Kuderer, N.M.; Lee, A.Y.; Arcelus, J.I.; Balaban, E.P.; Clarke, J.M.; Flowers, C.R.; Francis, C.W.; et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. *J. Clin. Oncol.* 2015, 33, 654–656. [CrossRef] [PubMed]
41. Blom, J.W.; Vanderschoot, J.P.; Oostindier, M.J.; Osanto, S.; van der Meer, F.J.; Rosendaal, F.R. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. *J. Thromb. Haemost.* 2006, 4, 529–535. [CrossRef] [PubMed]
42. Menon, S.P.; Rajkumar, S.V.; Lacy, M.; Falco, P.; Palumbo, A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. *Cancer* 2008, 112, 1522–1528. [CrossRef] [PubMed]
43. Schneeweiss, S.; Avorn, J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J. Clin. Epidemiol.* 2005, 58, 323–337. [CrossRef] [PubMed]
44. Zhan, C.; Miller, M.R. Administrative data based patient safety research: A critical review. *Qual. Saf. Health Care* 2003, 12, ii58–ii63. [CrossRef] [PubMed]

45. Tamariz, L.; Harkins, T.; Nair, V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. *Pharmacoepidemiol. Drug Saf.* 2012, 21, 154–162. [CrossRef] [PubMed]

46. Pauly, N.J.; Brown, J.D. Prevalence of low-cost generic program use in a nationally representative cohort of privately insured adults. *J. Manag. Care Spec. Pharm.* 2015, 21, 1162–1170. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).